A Wealth of Experience

We have collaborated with our clients on projects to research hematology, hematologic treatments, and complications and comorbidities of hematologic diseases. Our experience includes:

  • Allogeneic cord blood therapy 
  • Anemia
  • Blood transfusions
  • Hemophilia A
  • Hemophilia B
  • Myelofibrosis
  • Neutropenia
  • Polycythemia Vera
  • Pulmonary and venous embolism
  • Thrombocytopenia

Types of Projects

We have implemented studies to help our clients develop strategies in the hematology market and to develop and gain 
market access for products to treat hematologic diseases and complications arising from treatment of hematologic diseases.

Recent projects have included:

Our Experts

Xiaolei Zhou
Senior Director, Biostatistics
Shahnaz Khan
Executive Director, Market Access and Outcomes Strategy
Isobel Pearson
Senior Director, Health Economics, Health Technology Assessment
Jin Yang
Associate Director, Market Access and Outcomes Strategy
Lynda Doward
European Head, Patient-Centered Outcomes Assessment
Maria Fernandez
Senior Director, Market Access and Outcomes Strategy
Christopher Knight
Executive Director, Health Economics
Alicia Gilsenan
Vice President, Epidemiology
Annete Njue
Senior Director, Market Access and Outcomes Strategy
Dana DiBenedetti
Executive Director, Patient-Centered Outcomes Assessment
William L Herring
Senior Director, Health Economics
James Kaye
Senior Director, Epidemiology
Caroline Ling
Executive Director and HTA Specialist, Market Access and Outcomes Strategy
Kati Copley-Merriman
Vice President, Market Access and Outcomes Strategy
Keith Davis
Head, Health Economics
Joan Fortuny
Director, Epidemiology
Anne Heyes
Vice President, Head Market Access and Outcomes Strategy, Europe
Sorrel Wolowacz
Head, European Health Economics
Lia Gutierrez
Senior Director, Epidemiology

Selected Recent Hematology Publications

Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905.